Navigation Links
Lupus Foundation of Florida Applauds Support for Biosimilars Legislation

TALLAHASSEE, Fla., April 3, 2013 /PRNewswire-USNewswire/ -- The Lupus Foundation of Florida applauds the Health Policy committee of the Florida Senate for the passage of Senate Bill 732 out of committee.  The legislation will allow biologic medicines to be automatically substituted with interchangeable biosimilar medicines by pharmacists.  It would also ensure doctors are made aware of product substitution and ensure records of biosimilar substitution are kept for a reasonable amount of time.

"As a patient advocate, I overwhelmingly support this bill, which sets guidelines for safely introducing biosimilar drugs into the Florida pharmaceutical market," said Linda Reucher , Program Director of The Lupus Foundation of Florida. "Senator Grimsley's bill supports transparency of our healthcare system and provides the most vulnerable Floridians – the elderly and chronically ill – affordable access to these life-changing medications.  The bill will also ensure that doctors and their patients have the most accurate information available, which ensures the highest standard of medical care."

The Food and Drug Administration will likely approve biosimilars in the next year or two and they will soon be made available to patients.  Setting up a framework for patients to access biosimilars at pharmacy counters and ensuring the safe substitution and tracking of these highly complex products now – rather than down the road – makes sense.

As the name indicates biosimilars are similar, though not exact copies of their reference biologic product, and so even miniscule changes between a biologic and its biosimilar products might affect lupus patients and other patients taking biologic medicines.

There are approximately 1.5 million Americans with lupus and 90,000 in the state of Florida. When lupus fails to respond to traditional treatment methods, lupus patients may be prescribed biologics, particularly Rituxan and Benlysta. This is quite common in lupus nephritis which affects about half of all lupus patients.

About the Lupus Foundation of Florida
Since 1979, the Lupus Foundation of Florida has been serving Floridians affected by lupus. We are part of the Lupus Research Institute National Coalition whose funding of novel research brings the day closer when we can say, there is "Life without Lupus." Visit our website at

SOURCE Lupus Foundation of Florida
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):